sitagliptin

This page shows the latest sitagliptin news and features for those working in and with pharma, biotech and healthcare.

Novo’s diabetes pill defeats Merck’s Januvia in trial

achieved the target HbA1c level – 7% or lower – compared to 28% of those treated with sitagliptin after 52 weeks of treatment. ... The drug also hit the mark in the obesity setting, with patients achieving statistically significant and superior

Latest news

FDA’s year-end approvals take annual tally to 46

Merck and Pfizer picked up an FDA approval for SGLT2 inhibitor Steglatro (ertugliflozin) and combinations Steglujan (ertugliflozin and sitagliptin) and Segluromet (ertugliflozin and metformin) for use in adults with type 2
FDA panel backs CV claims for Novo Nordisk's Victoza

Merck &Co failed to win FDA approval for a similar claim for its DPP-4 inhibitor Januvia (sitagliptin) in April.
FDA won't add outcomes data to Januvia label

The US regulator has sent the pharma company a complete response letter for DPP-4 inhibitor Januvia (sitagliptin) and combination product Janumet (sitagliptin plus metformin) - along with extended release formulations - saying
Merck & Co and Pfizer take aim at diabetes with trio of new drugs

The marketing applications – filed in the US and EU – cover ertugliflozin as a monotherapy, a fixed-dose combination of ertugliflozin and Januvia (sitagliptin), and a fixed-dose combination of the SGLT2
EU clears AZ's FDA-rejected diabetes combination

The heart failure warning is particularly troublesome for AZ as it does not extend to Merck's top-selling DPP-4 inhibitor Januvia (sitagliptin), which is also being combined with SGLT2 ... A clean label suggests that sitagliptin/ertugliflozin will mount

More from news
Approximately 9 fully matching, plus 98 partially matching documents found.

Latest Intelligence

Market dynamics, marketing and analytics

The dotted horizontal line denotes market growth. The vertical dotted line indicates market leadership where Sitagliptin (Januvia) is the clear winner that is no longer growing at the speed of the
Interview: Christopher Boulton, AstraZeneca

sitagliptin) and Bristol-Myers Squibb (BMS), the original marketers of diabetes standard metformin under the brand name Glucophage.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Consultant Health Economics - London / Oxford: Negotiable

Events Manager – Med Comms – Surrey: Salary TBC

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

New Business Director - PR: Competitive Salary and benefits

Senior Account Director development role to Business Director, H...: Excellent package

Senior Account Executive, London, Medical Communications: Excellent package

Medical Writers Required – Cheshire: DOE

Medical/ Scientific Director: Salary TBC

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Associate Director: £75, 000-90, 000

Account Director: Excellent benefits

Project / Account Manager (Medical Education): Salary TBC

Senior Medical Writer: Competitive Salary

Client Services Director – Medical Education Agency – North West...: Salary TBC

Scientific Director / Editorial Team Leader: Great salary and benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Associate Medical Director: Highly Competitive

Medical Writers: Competitive Salary and Benefits

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Subscribe to our email news alerts

PMHub

Add my company

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...